blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3378489

EP3378489 - MONOCLONAL ANTIBODIES AND METHODS OF USE [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  06.08.2019
Database last updated on 31.08.2024
FormerRequest for examination was made
Status updated on  29.03.2019
FormerThe application has been published
Status updated on  24.08.2018
Most recent event   Tooltip04.06.2024New entry: Date of oral proceedings 
Applicant(s)For all designated states
Elanco Tiergesundheit AG
Mattenstr. 24A
4058 Basel / CH
[2018/39]
Inventor(s)01 / Rue, Sarah
Genomics Institute of the Novartis Research
10675 John Jay Hopkins Drive
San Diego, CA 92121 / US
02 / Eckelman, Brendan
Inhibrx LLC
11099 N. Torrey Pines Road Suite 1301
La Jolla, CA 92037 / US
03 / Deverauz, Quinn
11692 Frames Port Place
San Diego, CA 92126 / US
04 / Nasoff, Marc
14104 Rancho Santa Fe Lakes Drive
Rancho Santa Fe, CA 92067 / US
 [2018/39]
Representative(s)Greaves Brewster LLP
Copa House
Station Road
Cheddar, Somerset BS27 3AH / GB
[N/P]
Former [2018/39]Alexander, Sean Matthew
Eli Lilly and Company Ltd.
Erl Wood Manor
Sunninghill Road
Windlesham, Surrey GU20 6PH / GB
Application number, filing date18165199.325.10.2012
[2018/39]
Priority number, dateUS201161551918P26.10.2011         Original published format: US 201161551918 P
US201261699300P11.09.2012         Original published format: US 201261699300 P
[2018/39]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3378489
Date:26.09.2018
Language:EN
[2018/39]
Search report(s)(Supplementary) European search report - dispatched on:EP18.06.2018
ClassificationIPC:A61K39/395, A61K39/00, C07K16/00, C07K16/28, A61K45/06, G01N33/574
[2018/39]
CPC:
C07K16/2887 (EP,US); A61K39/3955 (US); A61K39/39558 (RU,US);
A61K45/06 (US); A61P35/00 (EP); C07K16/2896 (EP,US);
C07K16/3061 (US); G01N33/57426 (EP,US); C07K2317/20 (US);
C07K2317/24 (EP,US); C07K2317/33 (EP,US); C07K2317/52 (US);
C07K2317/56 (US); C07K2317/92 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/18]
Former [2018/39]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:MONOKLONALE ANTIKÖRPER UND VERFAHREN ZUR VERWENDUNG[2018/39]
English:MONOCLONAL ANTIBODIES AND METHODS OF USE[2018/39]
French:ANTICORPS MONOCLONAUX ET PROCÉDÉS D'UTILISATION[2018/39]
Examination procedure26.03.2019Amendment by applicant (claims and/or description)
26.03.2019Examination requested  [2019/18]
26.03.2019Date on which the examining division has become responsible
09.08.2019Despatch of a communication from the examining division (Time limit: M06)
12.03.2020Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
01.06.2020Reply to a communication from the examining division
13.12.2024Date of oral proceedings
Parent application(s)   TooltipEP12842976.8  / EP2771694
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
01.06.2020Request for further processing filed
01.06.2020Full payment received (date of receipt of payment)
Request granted
12.06.2020Decision despatched
Fees paidRenewal fee
30.07.2018Renewal fee patent year 03
30.07.2018Renewal fee patent year 04
30.07.2018Renewal fee patent year 05
30.07.2018Renewal fee patent year 06
31.10.2018Renewal fee patent year 07
31.10.2019Renewal fee patent year 08
23.10.2020Renewal fee patent year 09
25.02.2022Renewal fee patent year 10
12.10.2022Renewal fee patent year 11
13.10.2023Renewal fee patent year 12
Penalty fee
Additional fee for renewal fee
31.10.202110   M06   Fee paid on   25.02.2022
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XYI]WO03068821  (IMMUNOMEDICS INC [US], et al) [X] 1-4,7,13,14,16-20 * page 3, paragraph 3 - page 4, paragraph 1 * * example 9 * * example 10 * [Y] 8-10,15 [I] 5,6,11,12;
 [XYI]US2005271662  (BEALL MELISSA J [US]) [X] 1-4,7,13,14,16-20 * paragraphs [0114] - [0116]; example 6 * * paragraphs [0117] - [0119]; example 7 * * paragraphs [0107] - [0108]; example 3 * * figure 8; sequence 10 * * claims 29,32 * [Y] 8-10,15 [I] 5,6,11,12;
 [XYI]US2010061988  (HANSEN GENEVIEVE [US]) [X] 1-4,7,13,14,16-20 * the whole document * [Y] 8-10,15 [I] 5,6,11,12;
 [Y]WO2010117760  (BOEHRINGER INGELHEIM INT [DE], et al) [Y] 8-10,15 * the whole document *;
 [XYI]US2011091483  (BEALL MELISSA J [US]) [X] 1-4,7,13,14,16-20 * the whole document * [Y] 8-10,15 [I] 5,6,11,12;
 [XYI]WO2011109108  (VET THERAPEUTICS INC [US], et al) [X] 1-4,7,13,14,16-20 * page 24 * * paragraphs [0117] - [0123]; example 2 * * paragraphs [0135] - [0143]; example 4 * * paragraph [0144] - paragraph [0146] * * paragraph [0154]; example 5 * [Y] 8-10,15 [I] 5,6,11,12;
 [A]  - RUDIKOFF S ET AL, "Single amino acid substitution altering antigen-binding specificity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, (19820301), vol. 79, doi:10.1073/PNAS.79.6.1979, ISSN 0027-8424, pages 1979 - 1983, XP007901436 [A] 1-20 * the whole document *

DOI:   http://dx.doi.org/10.1073/pnas.79.6.1979
 [T]  - RUE SARAH M ET AL, "Identification of a candidate therapeutic antibody for treatment of canine B-cell lymphoma", VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, (20150218), vol. 164, no. 3, doi:10.1016/J.VETIMM.2015.02.004, ISSN 0165-2427, pages 148 - 159, XP029124750 [T] 1-20 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.vetimm.2015.02.004
 [T]  - K. WEISKOPF ET AL, "Eradication of Canine Diffuse Large B-Cell Lymphoma in a Murine Xenograft Model with CD47 Blockade and Anti-CD20", CANCER IMMUNOLOGY RESEARCH, US, (20161114), vol. 4, no. 12, doi:10.1158/2326-6066.CIR-16-0105, ISSN 2326-6066, pages 1072 - 1087, XP055481448 [T] 1-20 * the whole document *

DOI:   http://dx.doi.org/10.1158/2326-6066.CIR-16-0105
 [T]  - ITO DAISUKE ET AL, "Development of a novel anti-canine CD20 monoclonal antibody with diagnostic and therapeutic potential", LEUKEMIA & LYMP, INFORMA HEALTHCARE, UK, vol. 56, no. 1, doi:10.3109/10428194.2014.914193, ISSN 1029-2403, (20150101), pages 219 - 225, (20140616), XP009184989 [T] 1-20 * the whole document *

DOI:   http://dx.doi.org/10.3109/10428194.2014.914193
 [A]  - JUBALA C M ET AL, "CD20 EXPRESSION IN NORMAL CANINE B CELLS AND IN CANINE NON-HODGKIN LYMPHOMA", VETERINARY PATHOLOGY, AMERICAN COLLEGE OF VETERINARY PATHOLOGISTS, US, (20050701), vol. 42, no. 4, doi:10.1354/VP.42-4-468, ISSN 0300-9858, pages 468 - 476, XP009065299 [A] 1-17 * the whole document *

DOI:   http://dx.doi.org/10.1354/vp.42-4-468
 [A]  - IMPELLIZERI ET AL, "The role of rituximab in the treatment of canine lymphoma: An ex vivo evaluation", VETERINARY JOURNAL, BAILLIERE TINDALL, LONDON, GB, (20060501), vol. 171, no. 3, doi:10.1016/J.TVJL.2005.03.005, ISSN 1090-0233, pages 556 - 558, XP005368530 [A] 1-17 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.tvjl.2005.03.005
by applicantUS4816567
 US5545807
 US5545806
 US5569825
 US5625126
 US5633425
 US5661016
 WO2009080720
 WO2010022961
 US2011045536
    - JUBALA et al., Vet Pathol., (20050700), vol. 42, no. 4, pages 468 - 76
    - IMPELLIZERI et al., Vet J., (20060500), vol. 171, no. 3, pages 556 - 8
    - GRAVANIS et al., The Oncologist, (20101200), vol. 15, pages 1335 - 1343
    - TANG et al., Vet Immunol Immunopathol, (20010800), vol. 80, no. 3-4, pages 259 - 70
    - MACCULLUM et al., J. Mol. Biol, (19960000), vol. 262, no. 5, pages 732 - 745
    - "Standard conformations for the canonical structures of immunoglobulins", AL-LAZIKANI et al., J.Mol.Biol., (19970000), vol. 273, pages 927 - 948
    - AL-LAZIKANI et al., "Standard conformations for the canonical structures of immunoglobulins", J.Mol.Biol., (19970000), vol. 273, doi:doi:10.1006/jmbi.1997.1354, pages 927 - 948, XP004461383

DOI:   http://dx.doi.org/10.1006/jmbi.1997.1354
    - KOHLER; MILSTEIN, Nature, (19750000), vol. 256, page 495
    - JONES et al., Nature, (19860000), vol. 321, pages 522 - 525
    - RIECHMANN et al., Nature, (19880000), vol. 332, pages 323 - 329
    - PRESTA, Curr. Op. Struct. Biol., (19920000), vol. 2, pages 593 - 596
    - VERHOEYEN et al., Science, (19880000), vol. 239, pages 1534 - 1536
    - HOOGENBOOM et al., J. Mol. Biol., (19910000), vol. 227, page 381
    - MARKS et al., J. Mol. Biol., (19910000), vol. 222, page 581
    - COLE et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, (19850000), page 77
    - BOERNER et al., J. Immunol., (19910000), vol. 147, no. 1, pages 86 - 95
    - MARKS et al., Bio/Technology, (19920000), vol. 10, pages 779 - 783
    - LONBERG et al., Nature, (19940000), vol. 368, pages 856 - 859
    - MORRISON, Nature, (19940000), vol. 368, pages 812 - 13
    - FISHWILD et al., Nature Biotechnology, (19960000), vol. 14, pages 845 - 51
    - NEUBERGER, Nature Biotechnology, (19960000), vol. 14, page 826
    - LONBERG; HUSZAR, Intern. Rev. Immunol., (19950000), vol. 13, pages 65 - 93
    - GEBAUER et al., Curr. Opin. Chem. Biol., (20090000), vol. 13, no. 3, pages 245 - 255
    - NYGREN et al., FEBSJ., (20080000), vol. 275, no. 11, pages 2668 - 76
    - EBERSBACH et al., J. Mol. Biol., (20070000), vol. 372, no. 1, pages 172 - 85
    - KREHENBRINK et al., J. Mol. Biol., (20080000), vol. 383, no. 5, pages 1058 - 68
    - SKERRA, A., FEBSJ., (20080000), vol. 275, no. 11, pages 2677 - 83
    - SILVERMAN et al., Nat. Biotechnol., (20050000), vol. 23, no. 12, pages 1556 - 61
    - STUMPP et al., Drug Discov. Today, (20080000), vol. 13, no. 15-16, pages 695 - 701
    - GRABULOVSKI et al., J. Biol. Chem., (20070000), vol. 282, no. 5, pages 3196 - 3204
    - NIXON et al., Curr. Opin. Drug Discov. Devel., (20060000), vol. 9, no. 2, pages 261 - 8
    - KOIDE et al., Methods Mol. Biol., (20070000), vol. 352, pages 95 - 109
    - ZLOKARNIK et al., Science, (19980000), vol. 279, pages 84 - 8
    - CHARDES T. et al., FEBS Letters, (19990000), vol. 452, no. 3, pages 386 - 94
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.